Brent Seybold - VP, Device Development

Brent Seybold joined BioCardia in 2022 and brings over 25 years of medical device expertise with organizations ranging from seed-round start-ups to established global leaders.  Brent has extensive experience transforming both disposable and implantable medical device technologies from concepts to commercial product in the fields of thrombectomy & embolic protection, chronic total occlusion, ischemic stroke, hypertension and vertebroplasty.  He has previously served in executive and technical leadership roles at companies including LuMend, Parallax Medical, Genesis Medical Interventional, Micrus Endovascular and Vascular Dynamics. Brent has a Bachelor of Science degree in Mechanical Engineering from the University of California, Davis.

Peter Altman, Ph.D. - President & CEO View profile
David McClung, CFO View profile
Edward Gillis - Sr. VP of Devices View profile
Ian McNiece, Ph.D. - CSO View profile
Debby Holmes-Higgin, MPH - VP of Clinical View profile
Sujith Shetty - CMO/VP, Clinical & Regulatory View profile
Brent Seybold - VP, Device Development View profile

News

06 Dec

Fierce Biotech

BioCardia's off-the-shelf cell therapy for heart failure to enter first-in-human study
Read More
01 Dec

Empowered Patient Podcast

Optimizing Autologous Cell Therapy to Treat Cardiovascular Disease with Dr. Peter Altman
Read More
29 Oct

UW Health

UW Health Treats First Patient in U.S. with Investigational Cell Therapy for Heart Disease
Read More
29 Oct

Greenbay CBS

Neenah musician, educator pursues dream after being first in the world to undergo ‘Investigational Cell Therapy’
Read More
29 Oct

WBay.com

Neenah man gets new lease on life after trial heart procedure
Read More
04 Mar

Henry Ford Health System

Henry Ford Health System Studies Novel Cell Therapy Aimed at Improving Heart Failure Symptoms
Read More

press releases

16 Mar
2023 BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023
06 Mar
2023 Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting
01 Feb
2023 BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients
22 Dec
2022 BioCardia Letter to Shareholders
15 Dec
2022 BioCardia Announces $3.6 Million Private Placement of Common Stock
06 Dec
2022 BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS